Third-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA October 30, 2025 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session 2 Agenda Agenda Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., ...

Merck (MRK) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.32%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.01 per share when it actually produced earnings of $2.13, delivering a surprise of +5.97%.Over the last four quarters, the comp ...

Core Insights - Merck reported an increase in third-quarter profit and raised its full-year outlook due to the growing demand for its Keytruda cancer drug [1] Financial Performance - The company experienced higher profits in the third quarter, indicating strong financial health and operational efficiency [1] - The full-year outlook has been boosted, reflecting confidence in continued revenue growth driven by Keytruda [1] Product Demand - Demand for Keytruda, Merck's flagship cancer drug, continues to rise, contributing significantly to the company's revenue growth [1]

Financial Performance - Total sales for Q3 2025 reached $17,276 million, a 4% increase compared to Q3 2024[2] - Net income attributable to Merck for Q3 2025 was $5,785 million, reflecting an 83% increase year-over-year[2] - The earnings per share for Q3 2025 was $2.32, an increase of 87% from $1.24 in Q3 2024[2] - The income before taxes for Q3 2025 was $6,745 million, a 65% increase compared to $4,090 million in Q3 2024[2] - The tax rate for Q3 2025 was 14.2%, compared to 22.7% in Q3 2024[2] - The company reported a significant increase in net income for the year-to-date period, totaling $15,301 million, a 14% increase from $13,389 million in the same period last year[2] Sales Performance - Year-to-date sales for 2025 reached $48,611 million, showing no change from the same period in 2024[2] - Total sales for Q3 2025 reached $17,276 million, a 4% increase from $16,657 million in Q3 2024[10] - Pharmaceutical sales were $15,611 million, up 4% from $14,943 million in the same quarter last year[10] - Total sales for September YTD 2025 reached $48,611 million, a slight increase from $48,544 million in 2024[19] - Pharmaceutical sales were $43,299 million in September YTD 2025, remaining relatively stable compared to $43,358 million in 2024[19] Product Sales - Keytruda sales increased by 10% to $8,142 million compared to $7,429 million in Q3 2024[10] - Alliance revenue from Lynparza rose by 12% to $379 million, while Lenvima's revenue increased by 3% to $258 million[10] - Total vaccines sales decreased to $3,370 million from $3,675 million, a decline of 8% year-over-year[14] - Diabetes sales grew to $703 million, up from $592 million, reflecting a 19% increase[16] - Animal health segment reported sales of $1,615 million, a 9% increase from $1,487 million in the previous year[10] - Livestock sales increased by 16% to $1,023 million, while companion animal sales slightly decreased by 2% to $592 million[10] - Keytruda sales increased by 8% to $23,303 million in September YTD 2025, up from $21,646 million in 2024[19] - Gardasil/Gardasil 9 sales decreased significantly by 40% to $4,202 million in September YTD 2025, down from $7,032 million in 2024[19] - Total vaccines sales were $8,347 million in September YTD 2025, down from $10,755 million in 2024, reflecting a decline of 22.4%[23] - Total diabetes sales increased by 11.2% to $2,283 million in September YTD 2025, compared to $2,053 million in 2024[25] - Alliance revenue for Koselugo was $301 million in September YTD 2025, significantly higher than $114 million in 2024[25] Market Performance - The U.S. market contributed $27,371 million to total sales in September YTD 2025, a 14% increase from $24,089 million in 2024[19] - International sales decreased by 13% to $21,240 million in September YTD 2025, down from $24,455 million in 2024[19] - U.S. pharmaceutical sales increased by 15% year-over-year to $9.493 billion in Q3 2025, up from $8.227 billion in Q3 2024[28] - Japan's pharmaceutical sales decreased by 25% year-over-year to $693 million in Q3 2025, down from $919 million in Q3 2024[28] - Sales in China dropped significantly by 62% year-over-year to $377 million in Q3 2025, compared to $996 million in Q3 2024[28] Expenses and Income - Research and development expenses decreased by 28% in Q3 2025, totaling $4,234 million compared to $5,862 million in Q3 2024[2] - The cost of sales for Q3 2025 was $3,855 million, a decrease of 6% from $4,080 million in Q3 2024[2] - Selling, general and administrative expenses for Q3 2025 were $2,633 million, down 4% from $2,731 million in Q3 2024[2] - Interest income for Q3 2025 was $(96) million, compared to $(127) million in Q3 2024[31] - Total net other income/expense for Q3 2025 was $(238) million, an increase in loss compared to $(162) million in Q3 2024[31] - The company reported a total interest expense of $327 million in Q3 2025, slightly down from $330 million in Q3 2024[31] - Exchange losses increased to $56 million in Q3 2025 from $33 million in Q3 2024[31] Future Outlook - The company anticipates continued growth in key therapeutic areas and plans to expand its market presence through new product launches and strategic partnerships[10] - The full-year pharmaceutical sales guidance for 2025 is projected at $57.400 billion, reflecting a slight increase from $57.000 billion in 2024[28]

Core Insights - Merck reported strong third-quarter earnings and revenue, driven by high demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook due to lower estimated tariff costs [1][4]. Financial Performance - Keytruda sales exceeded $8 billion for the first time in a quarter, reaching $8.14 billion, a 10% increase year-over-year, although slightly below analyst expectations of $8.24 billion [2]. - Merck's net income for the quarter was $5.79 billion, or $2.32 per share, compared to $3.16 billion, or $1.24 per share, in the same period last year [6]. - The company reported total revenue of $17.28 billion for the quarter, a 4% increase from the previous year, surpassing expectations of $16.96 billion [10]. Guidance and Outlook - Merck adjusted its 2025 earnings forecast to between $8.93 and $8.98 per share, up from a previous range of $8.87 to $8.97 [3]. - The company expects full-year revenue to be between $64.5 billion and $65 billion, a narrower range compared to the previous guidance of $64.3 billion to $65.3 billion [5]. Challenges - Sales of Gardasil, a vaccine for HPV, fell to $1.75 billion, down 24% year-over-year, primarily due to reduced demand in China [8]. - Merck has halted shipments of Gardasil to China and does not plan to resume until at least the end of 2025, citing high inventories and soft demand [7]. Investor Focus - Investors are likely to seek updates on Gardasil's market presence in China and potential drug pricing agreements related to Trump's "most favored nation" policy [9].

Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China. ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results. ...

We recently published 11 Stocks Jim Cramer Discussed, Including A Potential “Worst Stock Ever”. Organon & Co. (NYSE:OGN) is one of the stocks Jim Cramer recently discussed. Organon & Co. (NYSE:OGN) is a women’s health company that provides fertility and contraceptive products. It’s been caught in a wave of controversy lately after CEO Kevin Ali stepped down after an investigation by the audit committee. Calling it the “worst stock ever,” Cramer remarked: “Did you notice the Orgenon quiescent, how they r ...

OPKO Health (NasdaqGS:OPK) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Speaker5Good afternoon and welcome to the OPKO Health third quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance during the conference call, you may signal an operator by pressing star followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw yo ...

Core Insights - The pharmaceutical maker's stock has decreased by 12% this year, indicating potential challenges in the market [1] Group 1 - The upcoming third quarter earnings report is anticipated, which may provide insights into the company's financial performance [1]